Dipeptidyl peptidase-4 (DPP-4) inhibitors (gliptins)

SGLT2 inhibitors and GLP-1 receptor agonists appear to offer the best protection against major adverse cardiovascular events in people with type 2 diabetes.

Empagliflozin, but not linagliptin, provides “clinically relevant” improvements in glycemic control versus placebo in children and adolescents with type 2 diabetes, report the DINAMO investigators.

Allowing people to try out medications for type 2 diabetes and choose their preferred one is a viable approach in the absence of a clear clinical indication, say the TriMaster investigators.

An algorithm based on real-world clinical data could support decisions between use of SGLT2 inhibitors and DPP-4 inhibitors in people with type 2 diabetes.

Fraser IP et al. Pediatr Diabetes 2018. doi: 10.1111/pedi.12790

Cai X et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0493-2

Okahata S et al. Diabetes Obes Metab 2018. doi: 10.1111/dom.13505

Qian D et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0482-5